Peptide lexicon
CJC-1295 DAC
GHRH analogue (Mod GRF 1-29) with a Drug Affinity Complex that binds covalently to albumin and extends the half-life to days.
| Substance class | Peptide |
|---|---|
| Sequence | Y-(D-A)-DAIFTNSYRKVLGQLSARKLLQDIMSR-K(Mal-PEG)-NH2 (Mod GRF 1-29 + Drug Affinity Complex) |
| Synonyms | DAC:GRF, Mod GRF 1-29 mit DAC |
Structure
CJC-1295 DAC is the tetrasubstituted GHRH(1-29) analogue Mod GRF 1-29 carrying a maleimide group on a C-terminal linker, which reacts with Cys34 of serum albumin.
State of research
Studies examined sustained growth hormone release and the rise in IGF-1 after single doses; preclinically, the pharmacokinetics of albumin-bound peptides.
Status
CJC-1295 DAC is not approved as a medicinal product and is on the WADA Prohibited List.
Literature
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future DirectionsJ Am Acad Orthop Surg Glob Res Rev, 2026 · PMID 41490200 · DOI 10.5435/JAAOSGlobal-D-25-00236
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine PhysiciansAm J Sports Med, 2026 · PMID 41476424 · DOI 10.1177/03635465251357593
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceSports Med, 2026 · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and PotionsSubst Use Misuse, 2016 · PMID 26771670 · DOI 10.3109/10826084.2015.1082595
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future PerspectivesInt J Mol Sci, 2026 · PMID 42123471 · DOI 10.3390/ijms27093890
